Immunohistochemistry Market: Global Share, Size, Growth, Trends & Outlook ( 2022 – 2032 )

Immunohistochemistry Market Insights

The Immunohistochemistry market is likely to reach a valuation of 3.9 Billion USD by 2032 from 2.1 Billion USD in 2022.The market for immunohistochemistry is likely to increase at a substantial rate during the forecast period due to factors such as the rising incidence of cancer and other chronic diseases, growing consumer awareness of the benefits, and technical advancements in the industry. The market is divided into segments based on end users, goods, applications, and region. F. Hoffmann-La Roche, Danaher Corporation, Merck KGaA, Thermo Fisher Scientific, and Agilent Technologies are a few of the market's main participants.

Immunohistochemistry Market Disease Understanding and Treatment Algorithm

Immunohistochemistry (IHC) is a laboratory technique used to detect the presence, location, and amount of specific proteins in cells and tissues, majorly used in diagnosis and treatment of cancer and other chronic diseases such as autoimmune, neurodegenerative and infectious diseases. It involves the following steps:

• Sample collection: A biopsy or surgical procedure is used to obtain a tissue sample from the patient.
• Sample preparation: To prepare the tissue sample for IHC analysis, it is processed and embedded in a paraffin block.
• Antibody staining: Specific antibodies are used to target and bind to particular proteins in the tissue sample. The antibodies are typically labelled with a fluorescent or enzyme-based dye, making the proteins visible under a microscope.
• Image analysis: The presence, location, and quantity of the particular proteins were further determined by examination under a microscope.
• Interpretation and diagnosis: A pathologist will make a diagnosis and suggest treatments based on the findings of the IHC analysis.
• Treatment: Based on the diagnosis, the patient will receive appropriate treatment, which may include surgery, radiation therapy, chemotherapy, immunotherapy, or a combination of these treatments.
• Monitoring: The patient will be closely monitored throughout the treatment process to ensure that the treatment is working and to make any necessary adjustments to the treatment plan

Immunohistochemistry Drugs Key Findings

Some key findings of the IHC drugs market include:

• The prevalence of cancer is rising, which is fueling demand for IHC medications because they are used in cancer diagnosis and treatment. This is also causing rapid growth in emerging nations.
• Technological developments: Examples include the creation of imaging techniques and more sensitive and focused antibodies.
• Increasing public awareness of IHC's advantages: The market for IHC is expanding as more individuals, particularly in developing nations, are becoming aware of IHC's advantages in disease diagnosis.
• Market consolidation: A small number of dominant companies, including F. Hoffmann-La Roche, Danaher Corporation, and Merck KGaA, dominate the market, which is highly consolidated.
• The frequency with which IHC is used as a companion diagnostic technique to choose patients for targeted therapy has increased.
• The high cost of IHC tests and reagents is a barrier to the technology's wide use, particularly in underdeveloped nations.
• By minimising the amount of time and human error involved in the process, automated IHC systems are becoming more and more popular.

Immunohistochemistry Emerging Drugs

There are several emerging drugs and immunotherapies in the field of immunohistochemistry (IHC) that are currently in various stages of development and clinical trials and it’s to be noted that it will take some time to know their full potential. These include:

• BiTE (bispecific T-cell engager) antibodies: These antibodies are made to draw in and activate the patient's own immune cells in order to target and destroy cancer cells.
• Checkpoint inhibitors: These molecules on the surface of cancer cells are the target of checkpoint inhibitors, which prevent cancer cells from evading the immune system.
• CAR-T cells: These are T cells that have been genetically modified to specifically target and destroy cancer cells in patients.
• Antibody-drug conjugates (ADCs): ADCs are a subset of targeted therapy that combine the cellular lethality of cytotoxic medicines with the specificity of monoclonal antibodies.
• Immunomodulatory drugs: By controlling the activity of immune cells, they are intended to improve the immune system's capacity to combat cancer.
• RNA-based therapies: They use small interfering RNA (siRNA) or messenger RNA (mRNA) to silence or enhance the expression of specific genes in cancer cells

Immunohistochemistry Market Driving Factors

The immunohistochemistry (IHC) market is driven by several factors, including:

• Governments are providing support around the world by investing in the development of new cancer treatments and diagnostic tools
• Immunohistochemistry is being used more frequently as a companion diagnostic tool to select patients for targeted therapy
• Increasing adoption of personalized medicine and the growing demand for targeted therapies
• The high unmet medical needs in the field of cancer and other chronic diseases
• The increasing demand for early diagnosis of cancer and other diseases
• Technological advancements and rising use of automation in IHC
• Increasing incidence of cancer
• Growing awareness of the benefits of IHC
• High growth in developing countries

Immunohistochemistry Market Challenges

The immunohistochemistry (IHC) market faces several challenges, including:

• High cost of IHC tests and reagents could be the barriers for widespread adoption of the technology, particularly in developing countries.
• Lack of standardization across different IHC techniques and protocols can make it difficult to compare results and make accurate diagnoses.
• Limited reimbursement for IHC tests and procedures can make it difficult for some patients to access the technology.
• The shortage of skilled professionals, such as pathologists, who are trained in IHC, can make it difficult for some patients to access the technology.
• Ensuring the quality and consistency of IHC tests and results is critical, but it can be a challenge due to the lack of regulatory oversight and guidelines.
• The competition with other diagnostic methods such as NGS, liquid biopsy, and others can be a challenge to the market growth.
• Limited availability of IHC tests and procedures in certain regions can make it difficult for some patients to access the technology.
• The technical complexity of IHC can be a challenge for some laboratories, which may require a significant investment in equipment, training, and personnel.
• Limited access to emerging technologies such as multiplexing, digital IHC, and AI-based analysis can be a hindrance for some laboratories and hospitals to adopt these technologies.
• Ensuring the quality and stability of reagents used in IHC can be a challenge, and it's important to have a good quality control and management system in place to maintain the accuracy of the results.

Immunohistochemistry Market Regional Synopsis

The global immunohistochemistry (IHC) market is segmented by region into North America, Europe, Asia Pacific, Latin America and Middle East & Africa. Apart from increasing incidence of cancer in each region, there are other growth drivers as mentioned below:

• North America: Dominates the global IHC market due to the presence of a large number of key players and the high healthcare expenditures.
• Europe: Holds significant market for IHC, driven by the availability of advanced healthcare infrastructure and the presence of a large number of key players.
• Asia Pacific: Expected to be the fastest-growing region for IHC due to the growing awareness of the benefits of IHC in disease diagnosis and the rapidly developing healthcare infrastructure.

Immunohistochemistry Market Key Players

The global immunohistochemistry (IHC) market is highly consolidated, with a chunk being the major players dominating the industry and a few of them include:

• F. Hoffmann-La Roche
• Danaher Corporation
• Merck KGaA is a German multinational pharmaceutical and chemical business that, through its subsidiary EMD Millipore, provides a broad range of IHC products.
• Thermo Fisher Scientific: A large biotechnology corporation that, through its subsidiary Life Technologies, sells a variety of IHC products, including reagents, tools, and software.
• Agilent Technologies: An American multinational company that offers a wide range of IHC products, including reagents, instruments, and software through its subsidiary Agilent Technologies.
• BioGenex: This privately held business provides a variety of IHC products, including reagents, tools, and software.
• Cell Signalling Technology: This privately held business provides a large selection of IHC items, such as reagents, tools, and software.
• Novocastra: A Leica Biosystems company, offers a broad selection of IHC products, including reagents, tools, and software.
• Abcam: A privately held business that provides a large selection of IHC goods, such as reagents, tools, and software.